Aberrant Promoter Methylation of Sparc in Ovarian Cancer

Epigenetic silencing of tumor suppressor genes is a new focus of investigation in the generation and proliferation of carcinomas. Secreted protein acidic and rich in cysteine (SPARC) is reportedly detrimental to the growth of ovarian cancer cells and has been shown to be epigenetically silenced in...

Full description

Bibliographic Details
Main Authors: Matthew J. Socha, Neveen Said, Yanshan Dai, Joseph Kwong, Preetha Ramalingam, Vuong Trieu, Neil Desai, Samuel C. Mok, Kouros Motamed
Format: Article
Language:English
Published: Elsevier 2009-02-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558609800250
id doaj-4ec7828989774802bac69cfa400d2504
record_format Article
spelling doaj-4ec7828989774802bac69cfa400d25042020-11-24T22:17:14ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022009-02-0111212613510.1593/neo.81146Aberrant Promoter Methylation of Sparc in Ovarian CancerMatthew J. Socha0Neveen Said1Yanshan Dai2Joseph Kwong3Preetha Ramalingam4Vuong Trieu5Neil Desai6Samuel C. Mok7Kouros Motamed8Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912, USAVascular Biology Center, Medical College of Georgia, Augusta, GA 30912, USAAbraxis BioScience LLC, Marina del Rey, CA 90292, USALaboratory of Gynecologic Oncology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USADepartment of Pathology, Medical College of Georgia, Augusta, GA 30912, USAAbraxis BioScience LLC, Marina del Rey, CA 90292, USAAbraxis BioScience LLC, Marina del Rey, CA 90292, USALaboratory of Gynecologic Oncology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USAVascular Biology Center, Medical College of Georgia, Augusta, GA 30912, USA Epigenetic silencing of tumor suppressor genes is a new focus of investigation in the generation and proliferation of carcinomas. Secreted protein acidic and rich in cysteine (SPARC) is reportedly detrimental to the growth of ovarian cancer cells and has been shown to be epigenetically silenced in several cancers. We hypothesized that SPARC is downregulated in ovarian cancer through aberrant promoter hypermethylation. To that end, we analyzed SPARC expression in ovarian cancer cell lines and investigated the methylation status of the Sparc promoter using methylation-specific polymerase chain reaction. Our results show that SPARC mRNA expression is decreased in three (33%) and absent in four (44%) of the nine ovarian cancer cell lines studied, which correlated with hypermethylation of the Sparc promoter. Treatment with the demethylating agent 5-aza-2′-deoxycytidine rescued SPARC mRNA and protein expression. Addition of exogenous SPARC, as well as ectopic expression by an adenoviral vector, resulted in decreased proliferation of ovarian cancer cell lines. Investigation of primary tumors revealed that the Sparc promoter is methylated in 68% of primary ovarian tumors and that the levels of SPARC protein decrease as the disease progresses from low to high grade. Lastly, de novo methylation of Sparc promoter was shown to be mediated by DNA methyltransferase 3a. These results implicate Sparc promoter methylation as an important factor in the genesis and survival of ovarian carcinomas and provide new insights into the potential use of SPARC as a novel biomarker and/or treatment modality for this disease. http://www.sciencedirect.com/science/article/pii/S1476558609800250
collection DOAJ
language English
format Article
sources DOAJ
author Matthew J. Socha
Neveen Said
Yanshan Dai
Joseph Kwong
Preetha Ramalingam
Vuong Trieu
Neil Desai
Samuel C. Mok
Kouros Motamed
spellingShingle Matthew J. Socha
Neveen Said
Yanshan Dai
Joseph Kwong
Preetha Ramalingam
Vuong Trieu
Neil Desai
Samuel C. Mok
Kouros Motamed
Aberrant Promoter Methylation of Sparc in Ovarian Cancer
Neoplasia: An International Journal for Oncology Research
author_facet Matthew J. Socha
Neveen Said
Yanshan Dai
Joseph Kwong
Preetha Ramalingam
Vuong Trieu
Neil Desai
Samuel C. Mok
Kouros Motamed
author_sort Matthew J. Socha
title Aberrant Promoter Methylation of Sparc in Ovarian Cancer
title_short Aberrant Promoter Methylation of Sparc in Ovarian Cancer
title_full Aberrant Promoter Methylation of Sparc in Ovarian Cancer
title_fullStr Aberrant Promoter Methylation of Sparc in Ovarian Cancer
title_full_unstemmed Aberrant Promoter Methylation of Sparc in Ovarian Cancer
title_sort aberrant promoter methylation of sparc in ovarian cancer
publisher Elsevier
series Neoplasia: An International Journal for Oncology Research
issn 1476-5586
1522-8002
publishDate 2009-02-01
description Epigenetic silencing of tumor suppressor genes is a new focus of investigation in the generation and proliferation of carcinomas. Secreted protein acidic and rich in cysteine (SPARC) is reportedly detrimental to the growth of ovarian cancer cells and has been shown to be epigenetically silenced in several cancers. We hypothesized that SPARC is downregulated in ovarian cancer through aberrant promoter hypermethylation. To that end, we analyzed SPARC expression in ovarian cancer cell lines and investigated the methylation status of the Sparc promoter using methylation-specific polymerase chain reaction. Our results show that SPARC mRNA expression is decreased in three (33%) and absent in four (44%) of the nine ovarian cancer cell lines studied, which correlated with hypermethylation of the Sparc promoter. Treatment with the demethylating agent 5-aza-2′-deoxycytidine rescued SPARC mRNA and protein expression. Addition of exogenous SPARC, as well as ectopic expression by an adenoviral vector, resulted in decreased proliferation of ovarian cancer cell lines. Investigation of primary tumors revealed that the Sparc promoter is methylated in 68% of primary ovarian tumors and that the levels of SPARC protein decrease as the disease progresses from low to high grade. Lastly, de novo methylation of Sparc promoter was shown to be mediated by DNA methyltransferase 3a. These results implicate Sparc promoter methylation as an important factor in the genesis and survival of ovarian carcinomas and provide new insights into the potential use of SPARC as a novel biomarker and/or treatment modality for this disease.
url http://www.sciencedirect.com/science/article/pii/S1476558609800250
work_keys_str_mv AT matthewjsocha aberrantpromotermethylationofsparcinovariancancer
AT neveensaid aberrantpromotermethylationofsparcinovariancancer
AT yanshandai aberrantpromotermethylationofsparcinovariancancer
AT josephkwong aberrantpromotermethylationofsparcinovariancancer
AT preetharamalingam aberrantpromotermethylationofsparcinovariancancer
AT vuongtrieu aberrantpromotermethylationofsparcinovariancancer
AT neildesai aberrantpromotermethylationofsparcinovariancancer
AT samuelcmok aberrantpromotermethylationofsparcinovariancancer
AT kourosmotamed aberrantpromotermethylationofsparcinovariancancer
_version_ 1725785836859949056